Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring

Are megamergers bad for business? Is it time for biotech's biggest gathering to find a new home? And can a "need" be anything but "unmet"?

Episode metadata supplied by the publisher feed · Published Jan 3, 2019

Embed this episode

Attribution link and audio player

NOW PLAYING

Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring

0:00 22:05

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

Jan 27, 2024 ·12m

Jan 19, 2024 ·9m

Jan 18, 2024 ·5m

Jan 14, 2024 ·6m

Jan 5, 2024 ·7m

Dec 29, 2023 ·7m

No similar podcasts found.

This episode is 22 minutes long.

This episode was published on January 3, 2019.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!